aztreonam + vancomycin

Aztreonam + vancomycin is a combination of two intravenous antibiotics used primarily as empirical therapy for serious infections where both Gram-negative and Gram-positive coverage is required, such as in febrile neutropenia or complicated skin and soft tissue infections. Aztreonam is a monobactam beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding protein 3 (PBP3), leading to cell lysis. It is active mainly against aerobic Gram-negative bacteria. Vancomycin is a glycopeptide antibiotic that inhibits cell wall biosynthesis in susceptible Gram-positive bacteria by binding to the D-alanyl-D-alanine terminus of peptidoglycan precursors, preventing cross-linking and weakening the bacterial cell wall. The combination provides broad-spectrum coverage against both Gram-negative (via aztreonam) and resistant Gram-positive organisms (via vancomycin), making it useful for initial empiric treatment before pathogen identification[1][2][3][4][5][6].

Brand names

VancocinAzactam

Other names

aztreonam plus vancomycinvancomycin plus aztreonam